logo
Share SHARE
FONT-SIZE Plus   Neg

4SC Says Its Resminostat Meets Primary Endpoint In Phase II Trial

4SC AG (FSCGF.PK) published encouraging efficacy data from the clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry.

The open-label, two-arm, international study investigated the safety and efficacy of resminostat both as a monotherapy and in combination with sorafenib for difficult to treat patient group, for which no approved treatment option is currently available.

According to the data now presented, which is based on an advanced data set, the primary study endpoint of halting the further progression of the particularly aggressive cancer in at least 20% of the patients treated and for at least 12 weeks has been achieved ahead of schedule in both therapy arms.

In general, resminostat has proven to be safe and well-tolerated. The most frequent side-effects observed were of a gastrointestinal nature.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
GoPro has just launched a facile camera, its smallest and lightest yet, as the action-camera sports maker seeks to further entice its adventure-seeking consumers. Oreo, the popular two chocolate wafers with a sweet crème filling in between has now got a new look. With about half the width of the regular Oreo, the new Oreo Thins will be thinner and slightly reduced in calorie. It will be available from July 13 with no change in its cookie taste and price tag. The Justice Department has initiated a probe to find out if airlines are colluding to limit seating capacity in order to benefit from higher airfares.
comments powered by Disqus
Follow RTT